VYD2311 not checked

Invivyd, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“VYD2311-SD (single-dose arm): Intramuscular injection dosing on Day 1 with VYD2311 and Intramuscular injection dosing Placebo (normal saline) on Day 30 and Day 60”In the company’s words, NCT07298434 on ClinicalTrials.gov
Tested for
COVID-19 (2 trials), Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine, COVID Long
Main trialPhase 3
“The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study.…”In the company’s words, NCT07298434 on ClinicalTrials.gov

Other drugs for COVID-19

All 44 drugs for COVID-19

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Aug 2026 Study of VYD2311 for the Prevention of COVID-19
Phase 2Not yet recruiting Jun 2027 Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome
Phase 1Active, not recruiting May 2025 A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
Phase 3Completed 15 Aug 2026 Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow VYD2311

Following is part of Solo: you see every change to VYD2311 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in